{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/herpes-simplex-oral/management/herpes-labialis-gingivostomatitis/","result":{"pageContext":{"chapter":{"id":"3270af1a-6907-5c03-9ffb-c4d827c56103","slug":"herpes-labialis-gingivostomatitis","fullItemName":"Scenario: Herpes labialis and gingivostomatitis","depth":2,"htmlHeader":"<!-- begin field ebfb3ddf-78ee-4712-9e7f-401354360072 --><h2>Scenario: Herpes labialis (cold sores) and gingivostomatitis</h2><!-- end field ebfb3ddf-78ee-4712-9e7f-401354360072 -->","summary":"Covers the management of herpes labialis (cold sores) and gingivostomatitis in primary care.","htmlStringContent":"<!-- begin item e88de4f4-b54b-4358-8631-503636293aec --><!-- begin field 87d50644-4d8c-4c42-bff1-acbc0156caf8 --><p>From age 6 months onwards.</p><!-- end field 87d50644-4d8c-4c42-bff1-acbc0156caf8 --><!-- end item e88de4f4-b54b-4358-8631-503636293aec -->","topic":{"id":"401dad14-da6a-5b54-bb3d-2cfea5661d4b","topicId":"5f875f0c-db78-44fb-b672-bd54c9216205","topicName":"Herpes simplex - oral","slug":"herpes-simplex-oral","lastRevised":"Last revised in October 2016","chapters":[{"id":"2106bbf3-357c-5e99-8faf-4898c1ca935e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"83c52d0f-97ef-5a31-8ff4-41d30aff63ad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"88707caf-63e9-5b1e-bd0d-adca6b1e4d1b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0b1ea486-a30d-554a-87c3-68b2a981d26d","slug":"changes","fullItemName":"Changes"},{"id":"96fd5acc-0417-54f9-8185-fd7234a33908","slug":"update","fullItemName":"Update"}]},{"id":"56d4e2ce-1a2c-5bbf-9a02-d7ec1fe80537","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"abbdfc66-bff5-502d-ad7d-32c81000d0f2","slug":"goals","fullItemName":"Goals"},{"id":"b3a9824a-ae33-5fa9-81e7-a932b005c125","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f2bb54c7-b5b0-5b30-a704-921dce3f32c9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d3f7ec4d-ecc0-5956-b6b6-22c492e1122f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9944dadf-7acf-5f24-8f20-c050c044edba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"425c65b2-de3b-5863-b73c-72199baee6f1","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"5749e0ab-cd7c-5a50-bc2c-ef816e9599c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"1d630313-1e41-59ae-8ae9-5cd26302276f","slug":"definition","fullItemName":"Definition"},{"id":"31a0a436-27cb-58e7-949b-76fb6dbd9c54","slug":"transmission","fullItemName":"Transmission"},{"id":"98ffdaac-76d5-54c1-93f5-7dd4a2f9148b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bf160e19-7acf-5ed0-9c7a-be8eeb5b5d1c","slug":"complications","fullItemName":"Complications"},{"id":"739ee047-f37b-56ca-ae40-7c3875158ee6","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"bc2ab338-32ce-50dc-8b2b-3546b85d2d9f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"78e575da-c305-5bf9-b61a-f062ae2c4eb5","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e37bcee1-69de-5e61-9294-81ff5642fa57","slug":"assessment","fullItemName":"Assessment"},{"id":"ed37f634-077a-5cf4-880d-5d2e9e5e5d9c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ca77797d-b745-54df-ae5b-ca78f5b20941","fullItemName":"Management","slug":"management","subChapters":[{"id":"3270af1a-6907-5c03-9ffb-c4d827c56103","slug":"herpes-labialis-gingivostomatitis","fullItemName":"Scenario: Herpes labialis and gingivostomatitis"}]},{"id":"059e9ce0-0874-50ea-b177-6ae9c92398c4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8416d8f1-2061-51a1-b6ab-29d314b7738e","slug":"analgesia","fullItemName":"Analgesia"},{"id":"eeff86e7-c71a-5781-a929-0698c0bcfc16","slug":"oral-antiviral-drugs","fullItemName":"Oral antiviral drugs"}]},{"id":"3a06d913-863d-5a7d-a6ce-6f327e1db685","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"981bfc0e-bf2d-528d-a298-5ed824004d46","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d4db274b-f8f9-559e-8053-48f1712ad1f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"1ee8a0ab-5883-561f-9aed-2524df466dfb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1c48988f-4b5b-512c-90dc-8f7341fd9a0f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e1757009-f8a2-561e-9c49-0048e0c195b9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9fbce5d9-f27e-5f7c-8744-4b00ad58e71d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d5966d8c-2014-541a-bd9b-fbab33577d44","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ca77797d-b745-54df-ae5b-ca78f5b20941","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"cfc34ee0-8355-563d-ba87-128c8cbade84","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 0965196a-0c30-4576-89ab-36bf03c4123b --><h3>When should I refer?</h3><!-- end field 0965196a-0c30-4576-89ab-36bf03c4123b -->","summary":null,"htmlStringContent":"<!-- begin item cc144633-661a-447b-ac78-02f9d1b6ba1f --><!-- begin field 30b6005d-cada-4d09-bdf7-aa36eb5a760a --><ul><li><strong>Consider admission to hospital if the person:</strong><ul><li>Is unable to swallow due to pain and is at risk of dehydration (especially in children).</li><li>Is immunocompromised with severe oral herpes simplex infection - they may need intravenous antiviral drug treatment.</li><li>Has a suspected serious <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/background-information/complications/\">complication</a> of oral herpes simplex infection - they may need intravenous antiviral drug treatment.</li></ul></li><li><strong>Arrange a suspected cancer pathway referral</strong> (for an appointment within 2 weeks) if there are any <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/diagnosis/assessment/\">red flags</a> suggesting oral cancer.</li><li><strong>Consider seeking specialist advice or referral</strong> to a specialist in infectious diseases or oral medicine, depending on clinical judgement, if the person:<ul><li>Is immunocompromised and has troublesome recurrent oral herpes simplex infection - prophylactic oral antiviral treatment may be needed.</li><li>Is pregnant (particularly near term) She should be advised that the risk of infecting her new baby by kissing are greatest when a woman acquires a new infection (new cold sore infection) in the third trimester, particularly within 6 weeks of delivery, as viral shedding may persist in the saliva and the baby is likely to be born before the development of protective maternal antibodies. </li><li>Has frequent (for example, 6 or more episodes in one year), persistent and/or severe episodes of recurrent oral herpes simplex infection - prophylactic oral antiviral treatment may be needed.</li><li>Has herpes simplex associated with recurrent <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/background-information/complications/\">erythema multiforme</a> - prophylactic oral antiviral treatment may be needed.</li><li>Has lesions which are refractory to <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/management/herpes-labialis-gingivostomatitis/#drug-treatment\">oral antiviral treatment</a> in primary care (if clinically indicated) after 5–7 days.</li><li>Has atypical lesions or the diagnosis is uncertain.</li></ul></li></ul><!-- end field 30b6005d-cada-4d09-bdf7-aa36eb5a760a --><!-- end item cc144633-661a-447b-ac78-02f9d1b6ba1f -->","subChapters":[{"id":"c273b30b-749a-53b5-b1fe-68b23f402ab7","slug":"basis-for-recommendation-d4f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ba4d010d-91f4-4e0f-abeb-c95e530c8ba5 --><h4>Basis for recommendation</h4><!-- end field ba4d010d-91f4-4e0f-abeb-c95e530c8ba5 -->","summary":null,"htmlStringContent":"<!-- begin item d4f653b4-1e22-4bac-b4f8-17088d692a4c --><!-- begin field 18b97da5-134c-410f-b9f0-f82254329653 --><p>The recommendations on when to consider admission or referral for a person with oral herpes simplex virus (HSV) infection are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Suspected cancer - recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">NICE, 2015</a>], a Cochrane systematic review <em>Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Glenny et al, 2009</a>] , and expert opinion in international review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Esmann, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Raborn and Grace, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Cernik et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Usatine and Tinitigan, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Williams et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Straface et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler and Balasubramaniam, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Sawleshwarkar and Dwyer, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">BMJ Best Practice, 2016</a>] and in a case report [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">George and Anil, 2014</a>].</p><h5>Considering hospital admission</h5><ul><li>The recommendation on admission if a person is at risk of dehydration is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Esmann, 2001</a>] and is pragmatic based on what CKS considers to be good medical practice, as these people may require intravenous fluids. </li><li>The recommendation on admission if there is a serious complication of oral herpes simplex infection is based on expert opinion in review articles, as these people may require intravenous antiviral drug treatment and other specialist intervention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Williams et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Primary Care Dermatology Society, 2016</a>].</li></ul><h5>Urgent referral for suspected cancer</h5><ul><li>The recommendation on urgent referral if there is suspected oral cancer is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">NICE, 2015</a>].</li></ul><h5>Seeking specialist advice or arranging referral</h5><ul><li>The recommendation on people who are immunocompromised with troublesome recurrent HSV infections is based on a Cochrane systematic review of people undergoing cancer treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Glenny et al, 2009</a>], expert opinion in a review article published by the British HIV Association (BHIVA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Williams et al, 2011</a>], expert opinion in review articles on oral herpes simplex infection and antiviral drug treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Raborn and Grace, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Usatine and Tinitigan, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Sawleshwarkar and Dwyer, 2015</a>], and the expert opinion of previous external reviewers of this CKS topic.<ul><li>Immunocompromised people are more at risk of severe, prolonged, or frequent recurrent oral disease, and are at increased risk of serious or life-threatening complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Cunningham et al, 2012</a>]. They may benefit from episodic or longer-term suppressive oral antiviral drug treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Williams et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler et al, 2012</a>].</li><li>Immunocompromised people may require higher doses or a longer duration of antiviral treatment than healthy people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Sawleshwarkar and Dwyer, 2015</a>], and may require virological evaluation for antiviral drug resistance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">BMJ Best Practice, 2016</a>], which requires specialist management.</li></ul></li><li>The recommendation on women who are pregnant is extrapolated from the fact that there is a well known risk that <em>genital </em>HSV infections in pregnancy can lead to transmission to the neonate, particularly at the time of delivery, if the mother is actively shedding HSV, causing potentially severe fetal and neonatal complications, or death [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">BASHH and RCOG, 2014</a>]. Evidence on the risk from maternal <em>oral </em>HSV infections is, however, very limited [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Straface et al, 2012</a>], and expert opinion from previous external reviewers of this CKS topic was divided regarding the significance of this risk.<ul><li>CKS therefore advises seeking specialist advice for women who are pregnant.</li></ul></li><li>The recommendation on people with frequent or severe recurrent HSV infections is based on expert opinion in review articles that suppressive oral antiviral treatment may be necessary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Cernik et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler et al, 2012</a>] and expert opinion in a case report [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">George and Anil, 2014</a>]. The threshold of 6 or more recurrences a year to define frequent infections is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Raborn and Grace, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Cernik et al, 2008</a>].</li><li>The recommendation on referral for people who have HSV complicated by recurrent erythema multiforme is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Raborn and Grace, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Esmann, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Primary Care Dermatology Society, 2016</a>] and in a case report on herpes gingivostomatitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">George and Anil, 2014</a>], that suppressive oral antiviral treatment can significantly reduce morbidity associated with recurrent oral infections.</li><li>The recommendation on people with lesions refractory to primary care management is based on expert opinion in a review article that further specialist investigation may be needed to clarify the diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler et al, 2012</a>]. Herpes simplex virus antiviral drug resistance is rare in healthy people (affecting less than 1% of people), but is more common in people who are immunosuppressed (affecting 3.5–10% of people) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Sawleshwarkar and Dwyer, 2015</a>], and this requires specialist management with alternative antiviral agents [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler and Balasubramaniam, 2013</a>].<ul><li>The recommendation to consider referral if there is no clinical improvement after 5–7 days of primary care management is based on the expert opinion of previous external reviewers of this CKS topic, and is pragmatic based on what CKS considers to be good medical practice.</li></ul></li><li>The recommendation on people with atypical lesions is based on expert opinion in review articles that further specialist investigation with viral culture, cytology, biopsy, or polymerase chain reaction (PCR) assessment may be needed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Usatine and Tinitigan, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler et al, 2012</a>], and is pragmatic based on what CKS considers to be good medical practice, as atypical lesions may be more extensive and aggressive than typical lesions, and may be a sign of underlying immunocompromise or immunosuppression.</li></ul><!-- end field 18b97da5-134c-410f-b9f0-f82254329653 --><!-- end item d4f653b4-1e22-4bac-b4f8-17088d692a4c -->","subChapters":[]}]},{"id":"89cd852d-7c51-5028-bc5c-68369f3aa9e1","slug":"drug-treatment","fullItemName":"Drug treatment","depth":3,"htmlHeader":"<!-- begin field 600ae196-36ce-486d-8761-89256e695f64 --><h3>What drug treatment should I offer for oral herpes simplex infections?</h3><!-- end field 600ae196-36ce-486d-8761-89256e695f64 -->","summary":null,"htmlStringContent":"<!-- begin item 9b1cfaa1-f0b1-48a5-91e4-466d682059e9 --><!-- begin field cc324999-eec5-4a64-9fd9-a775f43c6bc6 --><p><strong>The drug treatment of oral herpes simplex depends on the person's age, the frequency, severity, and distribution of lesions, and the person's immune status.</strong></p><p><strong>For people with primary or recurrent herpes labialis or gingivostomatitis infection:</strong></p><ul><li>Offer paracetamol and/or ibuprofen to treat symptoms of pain and fever, if needed, and there are no contraindications. For prescribing information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a> and <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</li><li>Do not routinely prescribe topical antiviral preparations, such as aciclovir or penciclovir.<ul><li>These products are available over-the-counter, and may be used by some people if they find them helpful, from the time of onset of prodromal symptoms before vesicles appear, if possible, until lesions have healed.</li></ul></li><li>Do not prescribe topical anaesthetic or analgesic preparations, mouthwash, or lip barrier preparations.<ul><li>These products are available over-the-counter, and may be used by some people if they find them helpful. Be aware that some topical analgesic preparations are not licensed for use in children. For further information on contraindications, cautions, drug interactions, and adverse effects of different preparations, see the <a href=\"http://www.medicines.org.uk/emc\" data-hyperlink-id=\"5f6228ce-b68c-40ed-a216-a93100c3662d\">electronic Medicines Compendium</a> or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"3a6af665-e858-4336-9423-a93100c3669e\">British National Formulary</a>.</li></ul></li><li>Do not routinely prescribe oral antiviral drug treatment for healthy people with herpes labialis.</li><li>Consider prescribing oral antivirals for healthy people with an episode of primary oral herpes simplex infection; recurrent herpes labialis if lesions are severe, frequent, or persistent; and recurrent gingivostomatitis (rare), depending on clinical judgement.</li><li>Consider prescribing oral antivirals for people who are immunocompromised with an episode of primary or recurrent oral herpes simplex infection, depending on clinical judgement.<ul><li>If an oral antiviral drug is indicated, advise the person to take the oral antiviral drug from the time of onset of prodromal symptoms before vesicles appear, if possible, until lesions have healed, for a minimum of 5 days.</li><li>The choice between the oral antiviral drugs aciclovir or valaciclovir depends on the preference of the person, drug cost, dosage regimen, likely adherence, and local prescribing policies. Note: famciclovir is not licensed for the treatment of oral herpes simplex infections. For more prescribing information on recommended drug doses, contraindications and cautions, and adverse effects, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/prescribing-information/oral-antiviral-drugs/\">Oral antiviral drugs</a> in the <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/prescribing-information/\">Prescribing information</a> section.</li></ul></li><li>If there is concern or uncertainty in the treatment of oral herpes simplex infection, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/management/herpes-labialis-gingivostomatitis/#referral\">Referral</a> - long-term oral antiviral prophylaxis may be needed for some people, following specialist advice.</li></ul><!-- end field cc324999-eec5-4a64-9fd9-a775f43c6bc6 --><!-- end item 9b1cfaa1-f0b1-48a5-91e4-466d682059e9 -->","subChapters":[{"id":"011b4f9f-5ea9-51a9-b908-742ee1e8038f","slug":"basis-for-recommendation-275","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 57d99b20-1185-4f37-ab8c-5bb0128625ca --><h4>Basis for recommendation</h4><!-- end field 57d99b20-1185-4f37-ab8c-5bb0128625ca -->","summary":null,"htmlStringContent":"<!-- begin item 27505dfc-1f02-4ddf-8ebb-52315db481c9 --><!-- begin field e4e74c89-9140-4f65-b9fa-be0c7be3fd6d --><p>The recommendations on the drug treatment of herpes labialis and gingivostomatitis infections are largely based on a British Medical Journal (BMJ) Clinical Evidence systematic review on herpes labialis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Worrall, 2009</a>], expert opinion in an American Academy of Oral Medicine (AAOM) <em>Clinical practice statement: Dental care for the patient with an oral herpetic lesion</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">AAOM, 2016</a>], and expert opinion in international review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Esmann, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Opstelten et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Usatine and Tinitigan, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Williams et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler and Balasubramaniam, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Hopper et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler and Sollecito, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Sawleshwarkar and Dwyer, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Goldman, 2016</a>] and expert opinion in the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">BNF 72, 2016</a>].</p><h5>Offering symptom relief for pain and fever</h5><ul><li>The recommendation on offering paracetamol and/or ibuprofen is based on the fact most episodes of herpes labialis and gingivostomatitis are mild and self-limiting, but they can be painful and cause fever and general malaise, which may respond to simple analgesia and antipyretics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Goldman, 2016</a>].</li></ul><h5>Not prescribing topical antiviral drug treatment</h5><ul><li>The recommendation not to routinely prescribe topical antivirals in primary oral herpes simplex infections is based on the fact that CKS found no good-quality evidence from randomized controlled trials (RCTs) that these agents are effective in reducing pain or time to healing compared with placebo or no treatment.<ul><li>A systematic review of interventions to treat primary oral herpes simplex infections noted that research data in this population group are limited, as people may not consult healthcare professionals until they have had several episodes of herpes labialis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Worrall, 2009</a>].</li></ul></li><li>The recommendation not to routinely prescribe topical antivirals in recurrent herpes labialis infections is based on limited moderate-quality evidence in a systematic review of twelve RCTs of healthy people, comparing topical aciclovir or penciclovir with placebo, that found these agents may reduce pain and healing time, but the results of the studies were inconsistent and of marginal clinical importance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Worrall, 2009</a>]. This is supported by evidence in a US review article on oral herpes simplex infections that topical antiviral treatment has no significant benefit over placebo for healthy people with recurrent herpes labialis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Usatine and Tinitigan, 2010a</a>].</li></ul><h5>Not prescribing topical anaesthetics or analgesics, mouthwash or lip barrier preparations</h5><ul><li>The recommendation on topical anaesthetics and analgesics, mouthwash and lip barrier preparations is based on the fact that CKS found no good-quality evidence on the effectiveness of these products for the treatment of herpes labialis, and expert opinion in the literature is conflicting.<ul><li>A systematic review of interventions for recurrent herpes labialis found no RCTs of sufficient quality to make a recommendation on whether topical anaesthetic agents reduce healing time in healthy people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Worrall, 2009</a>].</li><li>A US randomized placebo-controlled trial (n = 100) of children with acute painful infectious oral ulcers (of various aetiologies) in an emergency department setting found 2% topical lidocaine was not superior to placebo gel in improving oral fluid intake [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Hopper et al, 2014</a>].</li><li>CKS notes that some topical anaesthetic preparations are available over-the-counter, and expert opinion in an AAOM Clinical practice statement states 'topical anaesthetics, anti-inflammatory agents, and analgesics can help reduce the pain of recurrent herpes lesions' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">AAOM, 2016</a>], and expert opinion in a US dental review article recommends their use for some people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler and Balasubramaniam, 2013</a>].</li></ul></li><li>The recommendation on topical lip barrier preparations is based on expert opinion in a US dental review article that they may relieve symptoms for some people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler and Balasubramaniam, 2013</a>].<ul><li>In addition, expert opinion in a UK case report recommends the use of lip barrier preparations as a simple measure to prevent labial (lip) adhesions, which are a rare but potentially serious complication of herpes gingivostomatitis, which may require surgical intervention if severe [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Thomas, 2007</a>].</li></ul></li></ul><h5>Prescribing oral antiviral drug treatment</h5><ul><li>The recommendation on not routinely prescribing oral antiviral drugs for healthy people with mild-to-moderate recurrent episodes is based on the fact that most episodes of herpes labialis are self-limiting, the evidence on the benefits of oral antivirals is limited, and oral treatment needs to be initiated at the onset of prodromal symptoms which may be difficult for people in practice.<ul><li>Antiviral drugs inhibit viral replication, and most viral replication occurs within the first 24 hours of infection, so early initiation of treatment limits epithelial damage responsible for the development of clinical herpes simplex lesions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Esmann, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Cunningham et al, 2012</a>].</li></ul></li><li>The recommendation on considering prescribing oral antivirals for healthy people with a primary oral herpes simplex infection is extrapolated from evidence in a systematic review of two small RCTs of healthy children (n = 20 and n = 72) which found limited low-quality evidence that oral aciclovir may reduce the duration of pain and time to healing for a first attack of herpes gingivostomatitis compared with placebo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Worrall, 2009</a>]. This is supported by expert opinion in a US dental review article on the treatment of primary herpes labialis infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler and Balasubramaniam, 2013</a>] and a Canadian review article on the use of oral aciclovir for herpes gingivostomatitis in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Goldman, 2016</a>].</li><li>The recommendation on considering prescribing oral antivirals for healthy people with persistent, severe, or prolonged episodes of recurrent herpes labialis is based on a systematic review of five RCTs of healthy adults which found that oral aciclovir taken early in a recurrent episode (at the first sign of prodromal symptoms) may be more effective than placebo at reducing symptom duration and healing time. There were, however, no RCTs comparing early versus delayed intervention with oral antiviral agents, therefore the author highlighted it was difficult to draw conclusions about the timing of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Worrall, 2009</a>].</li><li>The recommendation on considering prescribing oral antivirals in a person who is immunocompromised with primary or recurrent infection is based on expert opinion in a British Medical Journal (BMJ) review article on antiviral drug treatments for herpes simplex virus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Sawleshwarkar and Dwyer, 2015</a>], expert opinion in a review article published by the British HIV Association (BHIVA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Williams et al, 2011</a>], and expert opinion in a US review article on oral mucosal diseases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler and Sollecito, 2014</a>], that these people are more at risk of severe, prolonged, or complicated oral herpes simplex infections.<ul><li>Oral antiviral drugs have comparable efficacy, so drug choice is dependent on patient wishes, drug cost, and the person's likely adherence to the drug regimen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Sawleshwarkar and Dwyer, 2015</a>].</li></ul></li></ul><!-- end field e4e74c89-9140-4f65-b9fa-be0c7be3fd6d --><!-- end item 27505dfc-1f02-4ddf-8ebb-52315db481c9 -->","subChapters":[]}]},{"id":"1e175a1e-cc5c-5fd0-9593-31bd2d9cf3e3","slug":"self-care-advice","fullItemName":"Self-care advice","depth":3,"htmlHeader":"<!-- begin field 21a587c2-715f-426e-bf97-a4dde9156606 --><h3>What self-care advice should I give?</h3><!-- end field 21a587c2-715f-426e-bf97-a4dde9156606 -->","summary":null,"htmlStringContent":"<!-- begin item e2e41d9c-d1d7-4091-b509-6db35bdabee3 --><!-- begin field 2c72bcb4-f836-415c-8837-b0f4432695f8 --><p><strong>Offer the following self-care advice:</strong></p><ul><li>Reassure the person/carer that oral herpes simplex infections are usually self-limiting, and that lesions should heal without scarring.</li><li>Advise on measures for symptom relief, such as:<ul><li>Paracetamol and/or ibuprofen to relieve pain and fever, if required, and there are no contraindications.</li><li>Adequate fluid intake to reduce the risk of dehydration.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/management/herpes-labialis-gingivostomatitis/#drug-treatment\">Topical</a> anaesthetics or analgesics, mouthwash and lip barrier preparations, which are available over-the-counter, and which some people may find helpful. Be aware that some topical analgesic preparations are not licensed for use in children. For further information on contraindications, cautions, drug interactions, and adverse effects of different preparations, see the <a href=\"http://www.medicines.org.uk/emc\" data-hyperlink-id=\"86fda9cd-51d3-470c-9f14-a93100b4ffa7\">electronic Medicines Compendium</a> or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"541026fb-a05f-4bb5-af58-a93100b50013\">British National Formulary</a>.</li></ul></li><li>Give information and advice about the nature and course of oral herpes simplex infections. Offer patient information leaflets, such as:<ul><li>The Herpes Viruses Association leaflet <a href=\"https://herpes.org.uk/cold-sores/\" target=\"_blank\" data-hyperlink-id=\"7bf31ca8-dfc6-474d-ac26-a93100b5001c\">About cold sores</a>.</li><li>The British Association of Dermatologists leaflet on <a href=\"http://www.bad.org.uk/for-the-public/patient-information-leaflets/herpes-simplex/?showmore=1&returnlink=http%3A%2F%2Fwww.bad.org.uk%2Ffor-the-public%2Fpatient-information-leaflets\" target=\"_blank\" data-hyperlink-id=\"54f20383-a2c7-4354-825f-a93100b50054\">Herpes simplex</a>.</li><li>The British Medical Journal leaflet on <a href=\"http://bestpractice.bmj.com/best-practice/pdf/patient-summaries/531984.pdf\" target=\"_blank\" data-hyperlink-id=\"548c17f4-bb63-4b11-844b-a93100b501e8\">Cold sores</a>.</li></ul></li><li>Give advice to minimize the risk of <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/background-information/transmission/\">transmission</a> to other people and autoinoculation:<ul><li>Explain that herpes simplex virus is easily transmitted to other people.</li><li>Avoid kissing and oral sex until all lesions have fully healed.</li><li>Do not share items that come into contact with lesions (for example lipstick or lip gloss).</li><li>Avoid touching the lesions, other than when applying topical preparations, which should be dabbed on rather than rubbed in to minimize mechanical trauma to the lesions. Topical treatments should not<em> </em>be shared with other people.</li><li>Wash hands with soap and water immediately after touching lesions.</li><li>Take care if using contact lenses, as there is a risk of transmission to the eye if lenses become contaminated.</li><li>Defer elective dental treatment until all lesions have fully healed.</li></ul></li><li>Inform parents or carers that children with herpes labialis or gingivostomatitis who are well do not need to be excluded from nursery or school.</li><li>Advise the person to try to avoid <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/diagnosis/assessment/\">trigger factors</a>, if possible.<ul><li>If sunlight is a trigger, advise the use of sunscreen or sunblock lip balm (sun protection factor 15 or greater), to help reduce recurrent episodes.</li></ul></li><li>Advise the person/carer to seek medical advice if their symptoms worsen (for example the lesion spreads, new lesions develop, or there is persistent fever or difficulty taking fluids), or no significant improvement is seen after 5–7 days.</li></ul><!-- end field 2c72bcb4-f836-415c-8837-b0f4432695f8 --><!-- end item e2e41d9c-d1d7-4091-b509-6db35bdabee3 -->","subChapters":[{"id":"0fd84d2e-697d-5447-b166-ed5c19736320","slug":"basis-for-recommendation-d58","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f332328f-af0a-4212-854b-8d1cf1399426 --><h4>Basis for recommendation</h4><!-- end field f332328f-af0a-4212-854b-8d1cf1399426 -->","summary":null,"htmlStringContent":"<!-- begin item d58084c3-2de1-4ec5-aaa8-de29b873e265 --><!-- begin field d537c001-eb72-49bb-9cd1-89297cfd3d86 --><p>The recommendations on self-care advice for people with oral herpes simplex infections are largely based on expert opinion in the American Academy of Oral Medicine (AAOM) Clinical practice statement <em>Dental care for the patient with an oral herpetic lesion</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">AAOM, 2016</a>] and expert opinion in international review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Esmann, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Usatine and Tinitigan, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">BMJ Best Practice, 2016</a>] and the Public Health England (PHE) document <em>Guidance on infection control in schools and other childcare settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">PHE, 2016</a>].</p><ul><li>Primary herpes labialis lesions usually resolve within 10–14 days of symptom onset without scarring [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Usatine and Tinitigan, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler et al, 2012</a>].</li><li>The recommendation on ensuring adequate fluid intake is based on the fact that severe oral pain may cause dehydration requiring hospitalisation for intravenous fluids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Esmann, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Goldman, 2016</a>].</li><li>The recommendation on deferring elective dental treatment until lesions are fully healed is based on the fact that aerosolization of the virus may occur during dental procedures, putting the person and oral healthcare providers at risk for possible infection or reinfection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Stoopler et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">AAOM, 2016</a>].</li><li>The recommendation that children with oral herpes simplex infection should not be excluded from nursery or school is based on the PHE document <em>Guidance on infection control in schools and other childcare settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">PHE, 2016</a>].</li><li>The recommendation to advise the person to seek medical review if symptoms worsen or do not improve significantly in 5–7 days is based on the expert opinion of previous external reviewers of this CKS topic, and is pragmatic, based on what CKS considers to be good medical practice.</li></ul><!-- end field d537c001-eb72-49bb-9cd1-89297cfd3d86 --><!-- end item d58084c3-2de1-4ec5-aaa8-de29b873e265 -->","subChapters":[]}]},{"id":"b15380ba-9c4d-580e-97d0-cd0a3be05eec","slug":"prevention","fullItemName":"Prevention","depth":3,"htmlHeader":"<!-- begin field 4520e98f-cc9e-4b4e-9e11-e955a651be77 --><h3>What measures may prevent recurrent oral herpes simplex infection?</h3><!-- end field 4520e98f-cc9e-4b4e-9e11-e955a651be77 -->","summary":null,"htmlStringContent":"<!-- begin item b281f0a0-5e65-4243-9d01-91e4ebcb0175 --><!-- begin field 717b4db4-07eb-4f23-9e07-b0845bf14ef2 --><ul><li><strong>For people with a history of recurrent oral herpes simplex:</strong><ul><li>If sunlight is a <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/diagnosis/assessment/\">trigger factor</a>, advise the use of sunscreen or sunblock lip balm (sun protection factor 15 or greater), to help reduce recurrent episodes.</li><li>Advise that the use of oral antiviral prophylaxis is not routinely recommended for healthy people.</li><li>Advise that the use of topical antiviral prophylaxis is not recommended.</li></ul></li><li><strong>Consider seeking specialist advice or arrange </strong><a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/management/herpes-labialis-gingivostomatitis/#referral\">referral</a> to a specialist in infectious diseases or oral medicine, depending on clinical judgement, to see whether oral antiviral prophylaxis is appropriate, for people:<ul><li>With a history of frequent, severe and/or persistent recurrent episodes.</li><li>Who are immunocompromised with a history of troublesome recurrent oral herpes simplex.</li><li>Who have herpes simplex associated with recurrent <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-oral/background-information/complications/\">erythema multiforme</a>.</li></ul></li></ul><!-- end field 717b4db4-07eb-4f23-9e07-b0845bf14ef2 --><!-- end item b281f0a0-5e65-4243-9d01-91e4ebcb0175 -->","subChapters":[{"id":"c37d0a6c-7479-51a3-8bc9-86303cc2d9fa","slug":"basis-for-recommendation-014","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 48e42858-6a79-4ce0-92f1-254c69dcc00a --><h4>Basis for recommendation</h4><!-- end field 48e42858-6a79-4ce0-92f1-254c69dcc00a -->","summary":null,"htmlStringContent":"<!-- begin item 014eba98-ab91-4e5f-8143-5573ba383746 --><!-- begin field 4eb288cc-66dd-44b5-8c4b-b454cd9f9ba6 --><h5>Use of sunscreen to prevent recurrent episodes</h5><ul><li>The recommendation on advising the use of regular sunscreen to prevent recurrent episodes of herpes labialis is based on a Cochrane systematic review (search date to May 2015) that found evidence from two randomized controlled trials (RCTs, n =111 in total) that sunscreen application significantly prevented recurrent herpes labialis triggered by ultraviolet light, however a third small RCT (n = 51) found no evidence of clinical benefit from sunscreen application, so the results were inconsistent [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Chi et al, 2015</a>].</li><li>A smaller British Medical Journal (BMJ) Clinical Evidence systematic review (search date to February 2009) found limited evidence from 2 small crossover RCTs (n = 57 in total) that sunscreen may reduce the frequency of recurrent episodes. It was noted that both studies used artificial exposure to ultraviolet light rather than sunlight to trigger herpes labialis episodes, and that one of the studies had methodological limitations due to the crossover design [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Chi, 2015</a>].</li></ul><h5>Topical antiviral agents not recommended</h5><ul><li>The recommendation on not prescribing topical antiviral agents to prevent recurrent episodes of herpes labialis is based on a Cochrane systematic review of two moderate-quality RCTs, which found no evidence that short-term use of topical aciclovir prevented recurrent episodes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Chi et al, 2015</a>]. This is supported by a subsequent BMJ Clinical Evidence systematic review of 3 low-quality RCTs on the effect of topical aciclovir 5% cream, which found no evidence that topical aciclovir was more effective than placebo at reducing recurrent episodes, symptoms such as pain, or healing time of recurrent lesions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Chi, 2015</a>].</li></ul><h5>Referral for specialist advice on oral antiviral prophylaxis</h5><ul><li>The recommendation on considering referral for specialist advice on prescribing prophylactic oral antiviral drugs for people with frequent, prolonged, and/or severe recurrent oral herpes simplex infections is based on limited evidence from two systematic reviews of healthy people.<ul><li>A Cochrane systematic review (search date to May 2015) of 32 RCTs (n = 2640) found that there was conflicting evidence on the benefit of short-term (less than 1 months' duration) oral aciclovir (using different study doses) in reducing recurrence rates. In contrast, longer-term (more than 1 months' duration) use of oral aciclovir and valacyclovir reduced the clinical recurrence rate, but it produced a very small reduction of 0.09 episodes per person per month. Overall, oral antiviral agents can prevent recurrent episodes, but the clinical benefit is small [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Chi et al, 2015</a>].</li><li>A smaller BMJ Clinical Evidence systematic review (search date to February 2009) of eight RCTs of interventions to prevent recurrent episodes of herpes labialis found limited evidence that prophylactic use of oral aciclovir and valaciclovir may reduce the number of recurrent episodes compared with placebo. The studies were, however, largely old, showed significant heterogeneity (using different antiviral drug regimens, population groups, and triggers for episodes), and overall were of limited methodological quality [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Chi, 2015</a>].</li></ul></li><li>The recommendation on considering referral for people who are immunocompromised with recurrent oral herpes simplex infections is based on a Cochrane systematic review (search date to November 2008) of 12 RCTs of people receiving cancer treatment, which found oral aciclovir was effective in preventing oral herpes simplex clinical lesions. This population group is at increased risk of serious and life-threatening complications from oral herpes simplex infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Glenny et al, 2009</a>].</li><li>The recommendation on considering referral for people with herpes simplex infections complicated by recurrent erythema multiforme is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Raborn and Grace, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Esmann, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">Primary Care Dermatology Society, 2016</a>] and a case report on herpes gingivostomatitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">George and Anil, 2014</a>], that long-term suppressive oral antiviral treatment can significantly reduce morbidity associated with recurrent oral infections.</li><li>CKS has therefore not routinely recommended the use of prophylactic oral antivirals for people with recurrent episodes in primary care, due to the limited evidence of benefit, but recommends considering referral for a specialist opinion.</li></ul><!-- end field 4eb288cc-66dd-44b5-8c4b-b454cd9f9ba6 --><!-- end item 014eba98-ab91-4e5f-8143-5573ba383746 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}